
Work Here?
LeMaitre develops medical devices for vascular surgery, focusing on peripheral vascular disease. Its main product, the LeMaitre Valvulotome, lets surgeons cut valves in peripheral veins without direct vision, improving treatment of lower-extremity arterial disease and helping to save legs; the portfolio also includes aortic grafts, vascular allografts, occlusion catheters, AV access systems, and collagen grafts. The devices are developed in-house and sold directly to hospitals, clinics, and vascular centers or via regional distributors, enabling surgeons to perform complex procedures more efficiently. By specializing in vascular devices with a global reach across 90 countries and a steady stream of R&D, LeMaitre aims to improve vascular treatment outcomes and broaden access to high-quality tools.
Industries
Industrial & Manufacturing
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Burlington, Massachusetts
Founded
1983
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$204.5M
Above
Industry Average
Funded Over
2 Rounds
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Remote Work Options
Hybrid Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Employee Referral Bonus
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Stock Options
Company Equity
Commuter Benefits
Employee Discounts
Company Social Events
LeMaitre Vascular data breach investigation: Edelson Lechtzin LLP probes class action claims after customer data is exposed. Sep 23, 2026, 23:19 ET National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the reported data breach. NEWTOWN, Pa., Sept. 23, 2026 /PRNewswire/ - Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at LeMaitre Vascular. Anyone who has received a data breach notice from LeMaitre Vascular, or who believes their personal information may have been exposed, can request a free case evaluation. LeMaitre Vascular data breach - at a glance * Company: LeMaitre Vascular is an international medical technology company focused on creating and supplying medical devices used to treat conditions affecting the peripheral blood vessels. * Reported: The company notified affected individuals and reported the incident to state regulators on or about September 18, 2026. * How it reportedly happened: Information regarding specific details of the breach has not been made publicly known. * When: The Company has not disclosed the exact dates on which the breach took place or when it was discovered. * Who may be affected: At least two Vermont residents have been affected by this breach. * Status: Certain details of the incident, including its full scope and the attacker's identity, remain unconfirmed or have not been publicly detailed. * Cost to you: Nothing. Click here for a free evaluation. What Personal Information May Be at Risk Based on public accounts and regulatory filings, the information potentially involved varied by individual and may include: * Social Security numbers * Government-issued identification numbers * Health records Who May Be Affected The investigation focuses on LeMaitre Vascular and at least two Vermont residents who were affected by this breach. Anyone who has received a data breach notification connected to this incident may face an increased risk of identity theft and fraud and is encouraged to come forward. Your Legal Options Edelson Lechtzin LLP is investigating a potential class action to pursue legal remedies on behalf of individuals whose sensitive personal data may have been compromised in the reported breach. A successful case could recover compensation for losses such as lost time, out-of-pocket costs, and loss of privacy, and could push LeMaitre Vascular to strengthen how it protects personal information. The firm will evaluate your rights and potential claims at no cost. Recommended Steps to Protect Yourself * Review your account statements and credit reports regularly and stay alert for suspicious activity. * Confirm whether your information was involved in the LeMaitre Vascular incident. * Preserve any letters or emails you received about the breach. * If credit monitoring was offered in your notice, consider enrolling before the stated deadline, and consider placing a fraud alert or security freeze with the three major credit bureaus. Contact Us for a Free Case Evaluation Speak confidentially with a data privacy attorney today: Marc Edelson, Esq., Edelson Lechtzin LLP, 411 S. State Street, Suite N-300, Newtown, PA 18940; Phone: 844-696-7492; Email: [email protected]; Web: www.edelson-law.com. About Edelson Lechtzin LLP Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to data breach litigation, the firm handles class and collective actions involving securities and investment fraud, federal antitrust violations, ERISA employee benefit plans, wage theft, and consumer fraud. Media and Partnership Inquiries: Use the contact information above to connect with our team regarding interviews, co-counsel opportunities, and referral partnerships. Legal Notice: This press release may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee a similar outcome. The reported data breach described above, and certain details concerning it, remain unconfirmed. SOURCE Edelson Lechtzin LLP
LeMaitre Vascular Data Breach: what affected individuals need to know. LeMaitre Vascular, a Burlington, Massachusetts medical device company, notified individuals in September 2026 of a data security incident that state filings indicate may have involved Social Security numbers, government ID numbers, and health records. Here is what the company disclosed and what affected individuals can consider doing. What happened in the LeMaitre Vascular Data Breach. A data security incident disclosed in September 2026. According to a notification letter LeMaitre Vascular, Inc. filed with the Massachusetts Attorney General, the company states that it recently experienced a data security incident that may have affected recipients' personal information. The letter is dated September 18, 2026, and the incident was also reported to the Vermont Attorney General on the same date. The company's letter does not state when the incident occurred, when it was discovered, or how it happened, and LeMaitre has not published a separate public statement describing the event. LeMaitre states that it has no evidence of the misuse or attempted misuse of any potentially impacted information. As with many incidents of this kind, details reported at this stage may be refined as additional filings become public. What information may have been involved. Social Security numbers, government IDs, and health records per state filings. The Massachusetts version of LeMaitre's letter does not itemize the categories of information involved. The Vermont Attorney General's public listing for the same incident identifies the affected data as Social Security numbers, government identification numbers, and health records. Because a Social Security number combined with a government ID and health information can be used for both financial and medical identity theft, affected individuals may face an elevated risk even though the company reports no evidence of misuse. Individual letters may describe the specific information that applied to each recipient. Who may be affected by the LeMaitre Vascular breach. Individuals whose information the company maintained. LeMaitre Vascular develops and sells medical devices for the treatment of peripheral vascular disease and is headquartered at 63 Second Avenue in Burlington, Massachusetts. The company's letter does not specify whether the affected individuals are employees, customers, patients, or others whose information it held, and it has not published a total number of affected individuals. State filings indicate a multi-state notification: reporting on the company's filing with the Massachusetts Office of Consumer Affairs and Business Regulation indicates roughly 955 Massachusetts residents were affected, and the Vermont Attorney General lists two Vermont residents. As of this writing, the incident does not appear on the U.S. Department of Health and Human Services breach portal. If you received a letter from LeMaitre Vascular referencing this incident or a Cyberscout enrollment code, that notice may indicate your information was among the data reported to have been affected. How LeMaitre Vascular responded and what protections are offered. Twenty-four months of TransUnion identity protection through Cyberscout. LeMaitre states that it takes the privacy and security of information in its possession seriously and that, out of an abundance of caution, it is offering affected individuals 24 months of complimentary identity protection services through TransUnion. The letter describes these services as including 24 months of credit and dark web monitoring, a $1 million identity fraud loss reimbursement policy, and fully managed identity theft recovery services. Individuals must enroll themselves using the enrollment code in their letter, and the deadline to enroll is December 18, 2026. Steps you can take to protect yourself. Practical precautions while the situation is reviewed. Given the categories of information reported in state filings, affected individuals may wish to consider a few precautionary steps: * Enroll in the TransUnion identity protection offer. If your letter includes an enrollment code, consider enrolling before the December 18, 2026 deadline. * Consider a credit freeze or fraud alert. Both are free through Equifax, Experian, and TransUnion; Massachusetts residents also have a statutory right to a security freeze noted in the letter. * Monitor Explanation of Benefits statements. Because health records may be involved, watch for medical claims or services you did not receive. * Review your credit reports. You are entitled to free credit reports at annualcreditreport.com. * Stay alert to phishing. Be cautious of unexpected emails, calls, or texts referencing LeMaitre or the incident, and verify any outreach independently before responding. This information is a general overview and is not legal advice; your situation may differ, and consulting a legal professional can help you understand rights that may apply to you. Talk to Wilshire Law Firm. Were you affected by the LeMaitre Vascular data breach? If your personal or health information may have been involved in the LeMaitre Vascular data breach, do you know what your options are? Its nationally recognized, award-winning team is here to help you understand your rights. Wilshire Law Firm offers free consultations and free case reviews with a legal professional, and Attorney & Law is available 24/7. Because Attorney & Law work on a contingency basis, there are no fees unless you get paid. Contact Wilshire Law Firm today to schedule your free case review and get your questions answered. Data Breach & Privacy September 21, 2026 Data Breach & Privacy September 21, 2026 Data Breach & Privacy September 21, 2026 Data Breach & Privacy September 21, 2026 Start your free case review. 4.9 out of 2,523 reviews * Available 24/7 * Hablamos Español * Nationally-Recognized Powerhouse Team As seen in: Attorney & Law'll contact you within minutes No fees unless you get paid. By submitting this form, you knowingly, voluntarily, and expressly consent to receive from Wilshire Law Firm telephone calls, emails, and SMS text messages, including those made using an automatic telephone dialing system (auto-dialer), artificial intelligence (AI), and/or pre-recorded or artificial voice messages. These communications are for the purpose of providing prompt consultation regarding your potential case. You understand that by providing your telephone number, you are granting permission to be contacted for this purpose, even if your number is on a federal or state Do-Not-Call registry. Consent is not required as a condition of retaining Wilshire Law Firm. Message and data rates may apply. You may revoke your consent to receive calls, texts, or emails at any time by replying "STOP" to any text message, calling 888-557-3271, filling out the form at wilshirelawfirm.com/do-not-contact or by any other reasonable method. For more information, refer to its Privacy Policy.
LeMaitre Vascular reported Q2 revenues of $70.38 million, up 9.6% year on year, but missing analysts' expectations by 1.7%. The company also missed EPS estimates significantly. Chairman and CEO George LeMaitre highlighted the international launch of Artegraft, now approved in 56 countries and accounting for 21% of sales. The company continues expanding its sales force and is undertaking six international warehouse expansions, with $376 million in cash. LeMaitre delivered the weakest performance against analyst estimates amongst its surgical equipment and consumables peers. The stock has fallen 21.8% since reporting earnings and currently trades at $82.68. The broader surgical equipment and consumables sector reported satisfactory Q2 results, with revenues beating consensus estimates by 0.8%, though next quarter's guidance came in 1.6% below expectations.
LeMaitre Vascular reported second-quarter revenue of $70.38 million, missing analyst estimates of $71.61 million despite 9.6% year-on-year growth. The medical device company's earnings per share of $0.70 also fell short of the expected $0.81. Management attributed the underperformance to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. Strong growth in the Artegraft line and European and Asian expansion partially offset these challenges. The company lowered its full-year revenue guidance to $276.3 million from $280 million. Operating margin improved to 29%, up from 25.1% in the prior-year quarter. CEO George LeMaitre indicated the company is evaluating clinical trial opportunities and addressing allograft supply issues through relocated tissue processing and expanded partnerships.
LeMaitre Vascular reported strong Q2 2026 results with 10% organic revenue growth, 72.1% gross margins, and adjusted earnings per share of $0.68, beating the consensus estimate of $0.66. Despite these solid fundamentals, shares declined following the earnings release as investors took profits. Prior to the May 5, 2026 Q1 results, LMAT shares had appreciated approximately 38% year-to-date. The stock closed at $79.00 on 5 August 2026, with a market capitalisation of $1.81 billion, down 22.85% over one month and 16.19% over 52 weeks. Asset management firm Conestoga Capital Advisors highlighted the medical device company in its Q2 investor letter, expressing confidence in LeMaitre's growth prospects. The firm cited the company's differentiated vascular product portfolio and consistent execution as key strengths.
Find jobs on Simplify and start your career today
Industries
Industrial & Manufacturing
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Burlington, Massachusetts
Founded
1983
Find jobs on Simplify and start your career today